i-Lumen AMD
Devicei-Lumen AMD transpalpebral microcurrent stimulation system
NCT Number: NCT06662162
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.
Participants will:
* Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months. * Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.
Interested in participating?
Request Info60 year and older
All sexes
Interventional
Not applicable
Sydney Eye Hospital, Sydney, New South Wales, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
i-Lumen AMD transpalpebral microcurrent stimulation system
Time frame: Month 3
Mean change in per-eye (treated study eye [unilateral] or treated primary study eye [bilateral]) from Baseline in distance BCVA letter score on the ETDRS VA chart, active vs sham.
Time frame: Month 3
Time frame: Month 6
Mean change in per-eye (treated study eye [unilateral] or treated primary study eye [bilateral]) from Baseline in distance BCVA letter score on the ETDRS VA chart, active vs sham.
Contact information is provided by the study sponsor or research team.
i-Lumen Scientific AUS PTY LTD
Industry
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2): a Multicentre, Randomised, Sham-controlled, Double-masked, Clinical Device Trial.
Acronym: i-SIGHT2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07160179
Age-Related Macular Degeneration, Eye Diseases
Carmel, Indiana, United States
View Trial DetailsNCT03011541
Abnormalities, Multiple, Age-Related Macular Degeneration
Westport, Connecticut, United States
View Trial DetailsNCT01866371
Age-Related Macular Degeneration, Choroid Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07556406
Age-Related Macular Degeneration, Eye Diseases
San Francisco, California, United States
View Trial Details